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Abstract 
Introduction: Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, 
but its effectiveness is limited and varies by age. New candidate vaccines are currently being 
investigated. In response to the declining incidence of TB, practices relating to BCG 
vaccination have changed in various countries in recent years. A valid cost-effectiveness study 
is therefore needed in order to assist decision-makers in the implementation of cost-effective 
strategies for BCG vaccination.  
Areas covered: Studies involving economic evaluations of BCG vaccination were reviewed in 
order to present current findings concerning a range of BCG vaccination strategies in a variety 
of regions, target populations, and vaccine types. The Quality of Health Economic Studies 
(QHES) instrument was used to assess the quality of the studies included in the analysis.  
Expert Opinion: Most of the studies showed a favorable economic profile of BCG vaccination. 
Selective strategies seem the most cost-effective option for low-incidence areas. Varying results 
on revaccination strategies did not lead to any conclusive finding on the cost-effectiveness of 
the strategies. A novel vaccine – either a BCG replacement or booster vaccine that provides 
better protection, especially in adults – has the potential to enhance the cost-effectiveness of 
vaccinating against tuberculosis.  
Keywords: tuberculosis, economic evaluation, Bacillus Calmette-Guérin (BCG), vaccination, 
strategies 
1. Introduction  
Tuberculosis (TB) is an infectious disease that caused 1.3 million deaths in 2017[1]. Although 
both the mortality and incidence rates are decreasing by 3% and 2% per year, respectively, the 
global burden of the disease has remained high, with around 10.4 million new cases in 2016 
[2]. Meeting the Sustainable Development Goals (SDGs) and the WHO “End TB Strategy” 
target will require further reductions in these rates: by 2035, a 95% reduction in mortality and 
a 90% reduction in incidence, relative to baseline in 2015 [3,4]. One essential component of 
efforts to achieve these goals is a prevention program utilizing a strategy involving existing or 
improved vaccines [1]. 
The Bacillus Calmette-Guérin (BCG) vaccine is the only vaccine available on the market to 
date. The efficacy of this vaccine is limited, however, and it varies by age. Although it is 
effective in infants, the duration of protection is limited and declines over time, for an average 
of no longer than 10 years [5]. It thus provides little, if any protection in adults, even though 
adult pulmonary TB is almost exclusively responsible for the transmission of the disease [6,7]. 
Millions of dollars have been invested in research and development aimed at finding a more 
effective and universally applicable TB vaccine [8]. At present, almost 20 candidate vaccines 
are being investigated, with only a few products entering the clinical trial pipeline [9].  
In recent years, BCG vaccination practices in various countries have changed in response to the 
declining incidence of TB [10]. According to a survey conducted in 2015, almost half of all 
European countries had changed their vaccination policies during the preceding decade [11]. 
For high-incidence countries, the World Health Organization (WHO) still recommends 
vaccinating all children at an early age (a universal strategy). Low-incidence countries may 
decide to vaccinate only high-risk populations, which consist predominantly of infants of 
immigrant parents originally from high-incidence countries (a selective strategy) [12]. In the 
United States, BCG vaccination is administered selectively to people who meet the criteria 
based on an expert TB examination, as recommended by the Centers for Disease Control and 
Prevention (CDC) [13]. If the resources available for the healthcare program are constrained, 
public health decisions concerning BCG vaccination policies should be based on both clinical 
outcomes and a health-economic evaluation.  
According to a review published in 2012, despite the sub-optimal efficacy of the vaccine, 
universal strategies have been suggested as the most cost-effective strategies for low and 
middle-income countries, while selective strategies could be considered in more affluent, low-
incidence countries 14]. This review also revealed wide variations in the methodologies used – 
accompanied by potential variations in quality – in the studies addressed [14]]. Given the large 
number of more recent health-economic evaluation studies, an updated review is warranted. 
The aim of this study is to present current findings by systematically detailing and comparing 
the outcomes of economic evaluation studies involving various BCG vaccination strategies in 
a variety of regions, target populations, and vaccine types. The review also includes a quality 
assessment of the studies based on the Quality of Health Economic Studies (QHES) tool. 
 
2. Methods 
2.1 Search strategy 
We performed a comprehensive search of the literature using the PUBMED and EMBASE 
databases, with no limitation on years or study population. The main keywords chosen for this 
study were quite similar to those used in the previous review [14]: “tuberculosis,” 
“vaccination,” and “economic evaluation.” We extended the search terms slightly, however, 
and we did not restrict the search to any particular type of tuberculosis (for details, see Appendix 
2). One of the researchers (AM) developed and ran the database search. The final search was 
run on September 24, 2018. In addition, a snowball search strategy involving the retrieval of 
potential additional studies in the reference sections of the papers identified in the main search 
was performed, in order to identify previously undetected papers.  
2.2 Eligibility criteria 
This study was conducted according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines. The inclusion criteria were as follows: studies were 
required to include a cost-effectiveness analysis (CEA), a cost-benefit analysis (CBA), or a 
cost-utility analysis (CUA), in addition to reporting the evaluations of cost and effectiveness 
separately; the types of BCG vaccines covered were the BCG vaccine that is currently applied, 
or a hypothetical, novel, or booster vaccine applied in humans; and the full text had to be 
available and written in English. There were no restrictions on study designs with regard to data 
collection and analysis: observational, modelling, and mathematical-calculation designs were 
all included. We excluded any study that lacked complete information on how the analysis was 
performed, as well as reviews and systematic reviews, editorial letters, guidelines, protocols, 
comments, news, correspondence, book chapters, and abstracts for posters or oral presentations.  
2.3 Study selection 
Two of the researchers (AM and SP) independently screened the titles, abstracts, and full text 
of the identified articles based on the inclusion and exclusion criteria. Any disagreements were 
discussed with the other authors until consensus was reached concerning the eligibility of the 
papers to be included.   
2.4 Data extraction 
Data extraction was performed by AM and verified by SP with regard to the following aspects: 
author names, year of publication, country of study, population, incidence of disease, 
vaccination coverage or uptake, strategy comparator, type of economic evaluation, 
immunization approach, type of study, perspective, discount rates, effectiveness outcomes, time 
horizon, currency and year, vaccine efficacy, duration of protection, cost per vaccination, cost 
per TB case, effectiveness, incremental cost-effectiveness ratio (ICER), and sensitivity 
analysis. In this case as well, consensus was achieved to resolve any discrepancies on data 
interpretation and verification of the validity of the extracted information.  
2.5 Quality assessment  
We used the Quality of Health Economic Studies (QHES) tool to assess the quality of the 
studies included. The QHES instrument is a validated method for assessing the quality of 
health-economic analyses, including 16 questions, each with specific weight values ranging 
from 1 to 9 [15]. Each score is multiplied by the weight to produce a total score, with a 
maximum score of 100. To minimize problems of interpretation, we assigned only full points 
in the assessment; no partial grading of individual criteria was done, even though several criteria 
consist of sub-items or subjective appreciations. Separate QHES evaluations were conducted 
independently by AM and SP. Any disagreements were discussed until the two reviewers 
reached consensus on the same interpretation.  
 
3. Results 
3.1 Selection Criteria 
The initial search of PUBMED and EMBASE yielded a total of 3481 titles. After removing 
duplications, 2373 articles were screened based on titles and abstracts, after which 48 articles 
were eligible for full-text review.  
After reviewing the 48 full-texts, 25 articles were excluded, leaving 23. Of the 25 articles 
excluded, 12 were excluded because the interventions did not meet the criteria. Notably, TB 
vaccination strategies were not specifically assessed in the study. An additional 10 studies were 
excluded due to partial evaluation; five evaluated only the cost and five described only the 
effectiveness of BCG vaccination. We further excluded one study that evaluated the 
effectiveness of BCG vaccine in chain distribution rather than explicitly considering the 
economic aspects [16], one study in which the input parameters for the economic evaluation of 
BCG vaccination program could not be retrieved [17], and one that did evaluate the cost-
effectiveness of BCG vaccination but that was rather  a review than it was original research 
[18]. Details are provided in Figure 1.  
The previous review by Tu and colleagues et al. included 13 studies [14]. We included all but 
one of the papers from this study [19], as we deemed the cost evaluation included in that paper 
incomplete according to present standards in health economics. Based on broader search terms, 
our review included two additional articles [20,21] published during the time-period of the 
previous review [14] as well as nine new articles published after 2011 through 2018. As 
mentioned, this study addresses a total of 23 articles.  
3.2 Characteristics of the studies included 
While four studies focused on non-specific countries (worldwide setting), most of the studies 
(19 of 23) were performed in country-specific settings: eight in European countries [22–29], 
four in Africa [30–33], four in Asia [20,34–36], and three in the United States [37–39]. In most 
cases, BCG vaccination was applied at a very young age: in 16 studies, it was applied in infants 
[21–23,25–27,30–35,40], in nine studies in school-aged children, either as a first 
vaccination[20,21,24,27,28,37,41] or as a revaccination [26,31,32,35], and two studies targeted 
children without specific age grouping [41,42]. Four studies reported BCG vaccination 
strategies aimed at adults, with a specific focus on healthcare workers [39], homeless people 
living in a shelter [38], and HIV-negative adolescents [27,40]. Most of the studies included 
economic evaluations of a licensed BCG vaccine available on the market, while two studies 
evaluated the MVA85A vaccine [30,33] (a potential candidate BCG booster vaccine), and four 
studies evaluated a hypothetical BCG vaccine with an assumed level of efficacy [31,32,39,40].  
3.3 Methodologies used in the included studies 
Nearly all of the studies (21 of 23) adopted a model-based design (i.e., decision-tree model, 
Markov model, or mathematical calculation) to perform an economic evaluation of BCG 
vaccination. Two remaining studies performed a trial-based cost-effectiveness analysis [23,37].  
In most cases (19 of 23), the analysis was conducted from a third-payer perspective: healthcare 
institutes [20,22–25,27,29,31], governments [30,36], employers [39], or un-specified payers 
[26,34,35,38,42]. Four studies were performed from the societal perspective [21,28,32,33], and 
one study reported from an incomplete societal perspective [37]. Two studies analyzed both 
healthcare and societal perspectives for purposes of comparison or performance in scenario 
analysis [40,41]. Most of the studies (19 of 23) included cost-effectiveness analyses (CEA),  
while three included cost-benefit analyses (CBA) [26,27,43], one study included both a CEA 
and a CBA [35], and one study provided a comparison of costs and benefits [28]. The most 
common clinical outcomes used within the studies were the number of cases averted and the 
number of deaths averted (15 of 21 studies). Other clinical outcomes included life years gained 
(LYG) [22,29,38,39,42], disability-adjusted life years (DALYs) [24,31,36,40], quality-adjusted 
life years (QALYs) [29] and hospitalization rates [23]. Of the model-based studies, various 
input parameters were observed, such as vaccine efficacy, duration of protection, cost of 
vaccination, and time horizon. The vaccine efficacy varied depending on the vaccination 
strategy and type of vaccine. The duration of protection varied from 5 to 40 years, with 15 years 
applied most often and 40 years used for a best scenario analysis in one study [36]. The cost 
per vaccination varied from USD 1 to 10; with the range USD 1-3 used most often, for a 
universal strategy. The studies applied higher cost per vaccination for selective and targeted 
strategies, ranging from USD 5 to 50; even more variation was found for revaccination or new 
(hypothetical) vaccines. The time horizon varied between 5 years [42], 10 years [30,33–
35,37,40,41], and 15 years [20–23,25,26,28,29]. Three studies were based on longer time 
horizons: 30 years [32], 50 years [39], and lifetime [24,36]. Three studies did not state the time 
horizon [27,31,38].  Details are provided in Table 2. 3.4 Vaccination approach 
Three main BCG vaccination approaches can be distinguished in the studies: 1) a universal 
strategy (11 studies) [20–22,25,27,28,34,36,37,41,42], which involves vaccinating the entire 
population; 2) targeted or other specific strategies (7 studies) [22–25,29,38,39], which involve 
vaccinating specific high-risk populations; and 3) revaccination strategies (3 studies) 
[26,31,35], which involve delivering a second or higher-order vaccination after the first 
vaccination. Seven studies assessed the cost-effectiveness of new and/or hypothetical vaccines 
[30,32,33,38–41]. Most studies addressed a low-incidence setting, with only five studies 
addressed high-incidence countries mainly focusing on the assessment of the new vaccines 
[30,32,33], one study on revaccination strategy [31], and one study on a universal strategy [20]. 
For studies evaluating two or more different populations and vaccination approaches, all 
analyses were included. Details are provided in Table 1. 
3.5 Universal vaccination strategies 
Universal BCG vaccination strategies were analyzed in 11 studies, either as the main 
intervention [21,27,28,34,37,38,41,42] or in comparison to selective strategies [22,25,29], no 
vaccination strategy [36], revaccination strategies [30,32,33], a proposed new TB vaccine [40], 
or other TB prevention strategies [20,38]. Universal strategies were most commonly applied in 
infants, with only four studies specifically addressing the vaccination of school-aged children 
[20,28,37,40]. All of the studies used model-based evaluations, except for one trial-based study 
by Pereira et al. [37].  
The input parameters used in the model-based studies were diverse. In the model-based studies, 
the BCG vaccine-efficacy rates used for the base case varied from 25% to 80% in infants. Some 
studies adopted efficacy rates that were lower (5% to 10%) or higher (100%) for the scenario 
analyses or as comparators. Most of the studies used protection periods of 10 years 
[30,33,34,37,40,41]  and 15 years [20–22,25,28], with two divergent studies using periods of 5 
years [42] and 30 years [32], respectively. One study did not specify the duration of BCG 
vaccine protection [27]. The ICER values were reported in various currencies, price years and 
outcome measures.  
When applied in high-incidence countries with TB-incidence rates above the threshold 
established by the International Union Against Tuberculosis and Lung Disease (IUATLD), a 
universal BCG vaccination against severe TB diseases was considered highly cost-effective at 
USD 206 (2002 USD) (CI 150–272)/LYG in a worldwide setting [42]. In 1980, a study 
conducted in Indonesia showed that combining universal BCG vaccination with other 
vaccination programs was more cost-effective than implementing the program independently: 
USD 101 vs USD 455 (1978 USD) per death prevented, respectively [20]. Meanwhile, the 
ICER values reported were higher when the strategy was applied in low-incidence countries: 
USD 35,950–USD 175,862 (2001 USD) per case prevented in Japan [34]; EUR 204,373 (2012 
EUR) per LYG[22] and EUR 139,557 (2014 EUR) per QALY[29] in Ireland, and USD 38,311 
(2001 USD) per case averted in Finland [25]. A model-based study in Taiwan, a moderate TB-
incidence country with 43 cases per 100,000 persons, reported that discontinuing universal 
vaccination would produce a small but robustly negative health impact, reflected by a projected 
increase of 82.9 cases within 10 years [36]. 
In addition, some studies evaluated universal strategies that were applied for both infants and 
older/school-aged children and, in some cases, adults. A study conducted in Brazil indicated 
that BCG vaccination of school-aged children as a catch-up strategy was cost-effective, even 
with an average vaccine-effectiveness rate of only 34% (8%–53%). The study demonstrated 
that it would cost less to vaccinate 381 children than it would to treat one patient with 
tuberculosis, with a cost-effectiveness ratio of 0.69 (vaccination vs treatment) [37]. A 
mathematical calculation study conducted in Austria showed that the cost savings from 
preventing the disease could compensate for the costs of vaccination for a strategy of universal 
vaccination in infants, with a ratio of 1.2, with a higher value (3.3) when applied in older 
children [27]. A 1976 study based on a societal perspective, however, reported that the costs of 
vaccination in school-aged children exceeded its monetary benefit [28].  
3.6 Selective strategies 
Seven studies assessed selective strategies for BCG vaccination – all performed in notably low-
incidence TB countries in Europe and the United States. While two studies examined a 
hypothetical BCG vaccination on specific high-risk adult populations – healthcare workers [39] 
and homeless people older than 35 years [38], the rest of the studies assessed selective strategies 
applying BCG vaccination only in infants at high risk of TB.  
A wide range of ICER values were reported for selective strategies. The ICER value reported 
in a study conducted in a Dutch setting was EUR 4500 (2005 EUR)/QALY, when the target of 
vaccination was expanded beyond immigrant infants from high-incidence countries to include 
immigrant infants from low-incidence countries but with high numbers of immigrants [24]. As 
noted by the authors, however, relevant uncertainties (e.g., with regard to vaccine efficacy and 
incidence) impede generalization of the results [24]. Two studies from Ireland reported that 
selective strategies were not considered cost-effective relative to no-vaccination strategies, with 
ICER values of EUR 143,233/LYG and EUR 340,520/LYG in studies conducted in 2016[22] 
and 2018 [29], respectively. Compared to universal vaccination, the selective strategy was 
substantially less costly (EUR 1,055,692), although it exhibited marginally reduced 
effectiveness, with 4.8 life-years lost relative to the universal strategy in Ireland [22]. A trial-
based study conducted in the Local Health Unit of Prato (Italy) indicated that a selective 
vaccination strategy had a positive effect, relative to the no-vaccination strategy, by 
significantly reducing the TB hospitalization rate [23]. A study conducted in Finland, which 
has a low incidence of TB (0.56 per 100,000 cases per year) reported that a universal strategy 
was not cost-effective relative to a selective strategy, with an ICER value of at USD 38,311 
(2001 USD) per case averted [25].  
In addition, when targeted at high-risk adults, BCG vaccination was reported to be a cost-saving 
strategy, even with effectiveness of only 40% (e.g., for people living in crowded shelters) [38]. 
Another study concluded that a hypothetical BCG vaccine with an assumed effectiveness rate 
of 50% would be more cost-effective than tuberculin testing  followed by preventive therapy in 
preventing TB cases among healthcare workers [39].  
3.7 Revaccination strategies 
Of the six studies evaluating revaccination in school-aged children, three evaluated 
revaccination strategies using a licensed BCG vaccine that was available in the market 
[26,31,35]. Two were conducted in low-incidence countries (i.e., Czech Republic [26] and 
Japan [35]), with incidence rates ranging from 1.1 to 20.2 per 100,000, depending on the age 
group. Another revaccination study was modelled according to the situation in South Africa, 
which is characterized by a high rate of TB transmission [31]. The vaccine-efficacy rate for 
revaccination strategies reported in the studies varied, with the highest efficacy assumed to be 
80% [31], the lowest being 0% [26], and a moderate efficacy rate of around 50% applied in 
some scenarios [31,35]. Two studies were based on a 10-year protection period [31,35], and 
one study applied a longer protection period of 15 years [26]. The two earlier studies (published 
in 1999 and 2002) concluded that revaccination with BCG was not a favorable strategy, as the 
costs exceeded the benefits [26] and the ICER value was high, at USD 108,378 (1999 USD) 
per case averted [35]. As demonstrated in the more recent model-based study, however, 
revaccination could be beneficial (with vaccine-efficacy rates ranging from 10% to 80%), 
especially when considering the prevention of TB transmission, with ICER values ranging from 
USD 52 to USD 4540 (2011 USD) per DALY averted [31]. 
3.8 Economic evaluation of new vaccines 
The three model-based studies evaluated a novel booster vaccine to be applied after the first 
BCG vaccination at birth [30,32,33]. The two studies conducted in South Africa assessed the 
MVA85A vaccine, which was applied at the age of 4 months and assumed to provide protection 
for 10 years [30,33]. However, each of these studies used a different vaccine-efficacy rate as an 
input parameter: a low efficacy rate of 17.3% (12.3%–22.3) [30] and a moderate rate of 60% 
(40%–70%) [33]. The first study concluded that adding a booster to the BCG vaccine alone was 
not a cost-effective strategy, based on the efficacy of MVA85A at that time (17.3%), although 
an efficacy rate of at least 41.3% would make the booster cost-effective [30]. The second study 
reported that, with a moderate vaccine-efficacy of 60% (40%–70%) and considering a societal 
perspective, MVA85A resulted in cost savings: around USD 14.82 million (USD 7.69–USD 
16.68) (2012 USD) [33]. The third study compared a hypothetical BCG replacement vaccine to 
the existing TB control program (i.e., current BCG vaccine at birth and DOTS [directly 
observed treatment, short course]). The study reported that the addition of a prime-booster 
vaccine, applied at age 10, was more cost-saving than a replacement vaccine applied only at 
birth, albeit with an assumed efficacy of 70%, as reflected in the net societal cost-saving results: 
USD 5.6 vs USD 3.6 million [32]. Similar findings were also reported by Knight et al., who 
demonstrated that a new TB vaccine targeting adolescents and adults – with 60% vaccine 
effectiveness and a 10-year protection period - would prevent more TB cases and yield lower 
ICER values than would a strategy targeting infants alone: 17 (11–24) vs 0.89 (0.42–1.58) 
million TB cases prevented and USD 378 (USD 150–USD 881) vs USD 1,692 (USD 634–USD 
4,603) per DALY averted, respectively [40]. It was also predicted that such investments in a 
better novel vaccine with an efficacy of 75% and a 10-year protection period would be 
profitable, with even higher values when considering productivity lost throughout the world 
setting [41].  
3.9 Key drivers of the analysis  
The key drivers of cost-effectiveness were derived from the sensitivity analyses reported in the 
studies included in this review. Of the studies included, four did not include sensitivity analyses 
[21,23,24,27], and one of these was a trial-based study [23]. Nine studies that did involve 
sensitivity analyses reported the key parameters influencing the cost-effectiveness analysis 
[22,25,30,32,34,35,37,38,41]. Other studies reported only the robustness of the results, due to 
changes in some parameters in certain scenarios (e.g., best-case or worst-case scenarios) 
[20,28,32,33]. Three studies reported multi-variate sensitivity analyses and described the range 
of the ICER values [33,42] or the probability of being cost-effective [26]. As expected, vaccine 
efficacy was the most commonly reported parameter influencing cost-effectiveness 
[22,25,30,32,34,35,37,38], with the second most commonly reported parameters being vaccine 
price or cost of vaccination [30,37,41]. Other parameters reported as key drivers were duration 
of vaccine protection; incidence of TB cases or TB deaths; vaccination coverage; and cost of 
TB cases. Details are provided in Table 1. 
3.10 Quality assessments 
We used the QHES tool to assess the quality of the studies included in this review. With a 
maximum score of 100, studies with scores above 50 are usually adequate for publication [15]. 
The quality of most of the studies included in this review were considered adequate; 15 studies 
scored above 75 [22,24–26,29,30,32–38,40,42], 6 scored between 50 and 75 
[21,23,28,31,39,41], and only two studies scored below 50 [20,27]. The complete final QHES 
scores for each study are provided in a supplementary appendix.  
The two items having the lowest scores in this review had to do with the sources of the estimates 
of relevant parameters and reporting of potential biases. The sources of estimates were fulfilled 
in only nine studies [22,23,26,29,30,34,36,37,42], with the rest of studies merely relying on 
assumptions for some parameters rather than deriving them from randomized control trials or 
previously published studies. Most of the studies  (12 of 23) did not explicitly discuss the 
potential biases of the analysis [23,25,31–34,37,40,42].  
4. Discussion 
4.1 Main Findings 
Three main vaccination approaches were evaluated in the studies and reviewed in our analysis: 
universal strategies, selective strategies, and revaccination strategies. Universal strategies 
targeting either infants or older children were identified as the most cost-effective option when 
applied in high-incidence countries. This finding suggests that the current BCG vaccine, 
although showing inconsistent efficacy, is still providing adequate protection in controlling TB 
in high-incidence countries. When applied to low-incidence countries, however, universal 
strategies were less cost-effective than no-vaccination or selective strategies. Nevertheless, in 
moderate-incidence countries (e.g., Taiwan), universal vaccination programs that are already in 
place remain beneficial as compared to no-vaccination policies: discontinuing BCG vaccination 
in such situations would still give rise to a small negative health impact which could not be 
neglected [36]. The IUATLD recommends that countries switch from a universal vaccination 
strategy if the incidence of TB is less than 5 cases per 100,000 population [36,44]. Although 
the WHO recommends BCG vaccination for infants, in some settings, universal strategies 
targeting adolescents or school-aged children were reported to be cost-effective as well 
[20,37,40]. A recent case-control study also indicated that BCG vaccination for school-aged 
children could provide up to 20 years of moderate protection [45]. Vaccinating high-risk adult 
populations (e.g., healthcare workers or adults living in crowded shelters) was also identified 
as a cost-saving strategy [38,39]. 
Various studies recommend the application of selective strategies, in most cases, as a 
replacement for universal strategies in low-incidence countries. In extremely low-incidence 
settings – such as the Netherlands (3 cases per 100,000) and Finland (0.56 cases per 100,000) 
– the selective vaccination of infants at high risk of TB was deemed beneficial, with the benefits 
exceeding the costs of vaccination [24,25]. For Ireland, with a TB incidence of around 7 cases 
per 100,000 population, the studies included in this review reported very high ICER values 
when comparing selective strategies to universal strategies [22,29]. As mentioned before, one 
limitation of these studies is that the very low incidence of TB makes it more difficult to 
generalize the results, due to uncertainty with regard to the efficacy of the BCG vaccine [24]. 
For switching from a universal strategy to a selective strategy, low-incidence countries, 
therefore, should carefully consider the IUALTD recommendation and a high-quality economic 
evaluation, which incorporates country-specific TB profiles, transmission effects, and societal 
impacts of the strategies.   
The current review suggests that revaccination strategies might not be cost-effective in low-
incidence countries [26,35], although a model-based study demonstrated that they could be 
beneficial in high-incidence countries [31], especially when accounting for the prevention of 
transmission. Although the studies conducted in low-incidence countries were deemed outdated 
(i.e., published in 1999 and 2002), they did provide an overview for the decision-makers in 
these countries at that time [26,35]. These studies were also in line with the WHO 
recommendation stating that, while repeating BCG vaccination does not confer any additional 
protection, it could incur more costs [46]. This recommendation was not based on cost-
effectiveness analysis, however, and many studies nevertheless argued that the benefits and 
safety of revaccination would outweigh the costs [47–49]. In one study, however, Roth et al. 
report that routine BCG revaccination, combined with other vaccination programs, was 
associated with an increase in overall mortality [50]. However, a recent phase 2 randomized 
control trial (RCT) study reported an encouraging result on the revaccination strategy in 
preventing TB infection in a high-transmission setting [51].Revaccination was intended to 
provide enhanced protection within the population of adults who are vulnerable to contracting 
TB, thereby posing a risk of transmission. Despite the potential benefits of revaccination 
strategies, the safety and high burden of vaccination in adolescents should be taken into 
consideration. 
In comparing the findings of this review with the earlier one [14], it appears that some 
conclusions remain unchanged, applying a universal strategy can be considered the optimal 
strategy when applied in high-incidence countries, while a selective strategy can be considered 
an appropriate choice in developed, low-incidence, countries. However, some notable findings 
are included in this updated review. For example, a selective strategy can only be considered  
cost-effective  in developed countries if TB incidence is extremely low, considerably below 5 
per 100 000 inhabitants. Another novelty was found for revaccination strategy, previously not 
considered to be cost-effective in developed countries – it has potential benefits, if applied in 
high-incidence and high-transmission settings [31].  
Our results indicate that a new, improved vaccine that would provide greater protection in older 
children and adults would be a more cost-effective strategy. This finding is in line with those 
of another review study on modelling a future TB vaccine, which predicts that a novel TB 
vaccine targeting older age groups (with pre-exposure and/or post-exposure efficacy) would 
have a better and more rapid epidemiological impact than would neonatal vaccination only[52]. 
Most new vaccines have been intended as prime boosters and applied in adolescence, with the 
expectation that they would provide additional protection beyond that of the current BCG 
vaccine, with the drawbacks associated with its waning effects [53]. The only new vaccine 
assessed in the studies analyzed in this review is MVA85A. According to a  randomized 
controlled trial, however, MVA85A has no significant efficacy [54]. Meanwhile, currently, two 
potential new TB vaccines have entered phase 2b trials. Firstly, H4:IC31 which showed a 
moderate efficacy of 30.4% against M. tuberculosis infection in a high-transmission setting 
[51]. Secondly, M72/AS01E which showed a vaccine efficacy of 50.4% against progression of 
M. tuberculosis infection into active pulmonary TB [55]. The modelling studies in this review 
consistently indicate that the new vaccine would be cost-effective if its vaccine efficacy against 
TB were to be at least around 40% [30,32,33]. Given that we found vaccine efficacyto be one 
of the key drivers of the cost-effectiveness of vaccines, further research and economic 
evaluations of the two aforementioned new vaccines are warranted. Further (cost-effectiveness) 
research would also need to focus on the other main drivers of cost-effectiveness:  the duration 
of protection, especially within the adult population, and the pricing of the new vaccines.  
In all, 23 studies were eligible for analysis in this review. Considering that we did not apply 
any restrictions on publication date or geographical area in our search, this is a relatively low 
number of economic evaluation studies. In the past seven years, however, a relatively large 
number of articles have been published, and the number of articles published since the previous 
review has doubled [14]. The most common objective of economic evaluations of BCG 
vaccination has been to assist decision-makers in re-evaluating the vaccination strategies in 
their countries (e.g., by shifting from a universal or revaccination strategy to a selective strategy, 
or even discontinuing BCG vaccination altogether). This could be the reason why most of the 
studies were conducted in low-incidence countries. Nevertheless, economic evaluation of BCG 
vaccination in high-incidence countries, which are known to have the highest use of BCG 
vaccination, is also needed in order to evaluate the current strategies of BCG policies and to 
predict the best vaccine profiles, with optimal cost-benefit ratios in light of limited resources, 
as is generally the case in low-income, high-incidence countries.   
Almost all of the studies addressed in this review were modelling studies. Such studies have 
become a useful assessment tool for predicting the impact of potential future TB vaccines [52]. 
The aspect that received the lowest QHES score among all studies included had to do with the 
sources of parameter estimates. Given that the efficacy of the BCG vaccine varies considerably 
across populations and regions, as established in clinical trials and observational studies [5], 
future economic-evaluation studies should review the best available age-specific and country-
specific evidence in order to estimate the input parameters for the analysis. This finding also 
highlights a clear need for broader research on the current efficacy and effectiveness of the 
BCG vaccine, representing the best estimates in low-incidence and high-incidence countries, 
thereby potentially improving the reliability of country-specific analyses. In addition, static 
modelling was most often applied within the included studies, represents a straightforward 
calculation of the cost-effectiveness analysis. However, dynamic modelling, which 
incorporates effects on TB transmissions, could provide better estimates for the analysis, 
apparently for critical strategies such as switching to a universal strategy in low-to-moderate 
incidence countries, applying a revaccination strategy in high-incidence high-transmission 
countries, or assessing the new vaccines. Moreover, most studies in this review used a third 
payer perspective for the analysis which does not capture the potential effects on society, such 
as productivity losses and some catastrophic costs. 
4.2 Strengths and Limitations 
This review involved a systematic search of two large databases – PubMed and EMBASE –
following PRISMA guidelines. In addition, we applied strict inclusion criteria and did not 
impose any limitations on the year of publication. We therefore expected to find all studies 
containing relatively complete economic evaluations since the introduction of the BCG 
vaccination in 1921. We also assessed the quality of the studies included using a validated 
instrument: QHES. Despite its strengths, however, this systematic review is also subject to 
limitations. First, the studies included in the review had flaws in terms of methodology and the 
input parameters used in the analyses. It is therefore difficult to make direct comparisons and 
to draw straightforward conclusions from our review. However, combined with transferability 
assessments, this review could assist decision-makers in countries with limited resources in 
making such economic evaluations, by providing an overview of the cost-effectiveness 
strategies applied in BCG policies in country-specific settings. Second, because the review was 
limited to studies from peer-reviewed publications, which excluded those published by 
manufacturers or marketing agencies, as well as some abstracts for which the full text could not 
be retrieved. We also might have missed some studies in locally or regionally reputed journals 
in low-income countries, as we included only studies that were indexed in PUBMED and 
EMBASE.    
5. Conclusions 
Most of the studies included in our analysis exhibited a favorable economic profile for the use 
of BCG vaccination against TB. Universal strategies remain the most cost-effective for high-
incidence countries. Although strategies clearly targeting infants are considered cost-effective, 
the vaccination of adolescents as a catch-up strategy might also be cost-effective in some 
settings.  Countries with low to moderate incidence rates might consider selective strategies, as 
they appear to be more cost-effective than discontinuing vaccination altogether. Given the 
variations in the results reported for revaccination strategies, we are unable to draw conclusions 
on the cost-effectiveness of BCG revaccination. In the future, a new vaccine that offers better 
protection within the adult population would be the most cost-effective investment in research 
and development.  
6. Expert opinion  
Based on the 23 studies on the economic evaluation of BCG vaccination included in this review, 
we have demonstrated that universal vaccination at birth remains the most cost-effective 
strategy for high-incidence countries. Given that no new vaccines replacing BCG have been 
licensed and made ready to enter the market to date, the current BCG vaccine will continue to 
be the most cost-effective strategy for universal application in infants for the next five years. 
At the same time, given that the incidence of TB is declining in most developed countries, some 
countries with incidence rates lower than that recommended by the IUATLD (5 cases per 
100,000)-particularly in the European region, the United States, and some Asian countries or 
parts thereof- might need to re-evaluate their current BCG policies, thus considering to 
reallocate the budget to strengthening other components of their TB control programs (i.e., early 
diagnosis and appropriate treatment).  Subject of further research should include the efficacy of 
BCG vaccination in adult populations, or the cost-effectiveness of vaccinating adolescents or 
adults in some settings, as with catch-up strategies for school-aged children or as a preventive 
measure in high-risk adult populations (e.g., healthcare workers or people living in crowded 
shelters). In addition, given the lack of evidence on the efficacy of revaccination, this strategy 
is not considered cost-effective for low-incidence countries. At the same time, however, second 
BCG vaccination could be beneficial in high-incidence countries, especially in light of the high 
transmission rate. Further evaluation is required, taking into account the best evidence 
concerning the safety and burden of revaccination strategies. In addition to targeting the 
potential replacement of BCG vaccinations for infants, there is an urgent need for novel 
vaccines that meet the SDGS and WHO targets, in order to reduce the TB burden worldwide. 
Future research and development with regard to novel vaccines should address the 
shortcomings of the current BCG vaccine: waning protective effect over time, thereby resulting 
in little or no protection in adult populations, in addition to the low overall efficacy of the 
vaccine in settings characterized by a high TB burden. Such boosters or replacement vaccines 





• Universal BCG vaccination remains cost-effective for high-incidence countries. 
• Countries with low to moderate incidence rates should carefully consider applying a 
selective strategy by vaccinating high risk-infants, in light of the recommendations of 
IUATLD and based on country-specific economic-evaluation studies. 
• Further evaluation is needed regarding the implementation of vaccination for older 
children or adult populations for first vaccination or second vaccination (i.e., 
revaccination).  
• Future research on novel TB vaccines could focus on a new, improved vaccine that 
could provide better protection to infants, as well as within the adult population. 
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